Oncogene-induced senescence does not require the p16 INK4a or p14ARF melanoma tumor suppressors

Journal of Investigative Dermatology

Volumn 129, Issue 8, 2009, Pages 1983-1991

  Haferkamp, Sebastian ^a   Scurr, Lyndee L ^a   Becker, Therese M ^a   Frausto, Monika ^a   Kefford, Richard F ^a   Rizos, Helen ^a  

^a WESTMEAD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A;

ARTICLE; CELL CULTURE; CONTROLLED STUDY; HUMAN; HUMAN CELL; MELANOCYTE; MELANOMA; NEVUS CELL; NUCLEOTIDE SEQUENCE; ONCOGENE; ONCOGENE N RAS; PRIORITY JOURNAL; RNA INTERFERENCE; SENESCENCE;

CELL AGING; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P16; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENES, RAS; HUMANS; MELANOCYTES; MELANOMA; PROTO-ONCOGENE PROTEINS C-AKT; TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEINS;

EID: 67651098636     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2009.5     Document Type: Article

References (56)

1. Adams PD (2007) Remodeling of chromatin structure in senescent cells and its potential impact on tumor suppression and aging. Gene 397:84-93
2. Bauer J, Curtin JA, Pinkel D, Bastian BC (2007) Congenital melanocytic nevi frequently harbor NRAS mutations but no BRAF mutations. J Invest Dermatol 127:179-82
3. Ben-Porath I, Weinberg RA (2005) The signals and pathways activating cellular senescence. Int J Biochem Cell Biol 37:961-76
4. Bloethner S, Chen B, Hemminki K, Muller-Berghaus J, Ugurel S, Schadendorf D et al. (2005) Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines. Carcinogenesis 26:1224-32
5. Bond J, Jones C, Haughton M, DeMicco C, Kipling D, Wynford-Thomas D (2004) Direct evidence from siRNA-directed "knock down" that p16(INK4a) is required for human fibroblast senescence and for limiting ras-induced epithelial cell proliferation. Exp Cell Res 292:151-6
6. Braig M, Lee S, Loddenkemper C, Rudolph C, Peters AH, Schlegelberger B et al. (2005) Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 436:660-5
7. Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, Niki M et al. (2005) Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436:725-30
8. Cheung M, Sharma A, Madhunapantula SV, Robertson GP (2008) Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development. Cancer Res 68:3429-39
9. Chin L, Garraway LA, Fisher DE (2006) Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev 20:2149-82
10. Chin L, Pomerantz J, Polsky D, Jacobson M, Cohen C, Cordon-Cardo C et al. (1997) Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. Genes Dev 11:2822-34
11. Collado M, Gil J, Efeyan A, Guerra C, Schuhmacher AJ, Barradas M et al. (2005) Tumour biology: senescence in premalignant tumours. Nature 436:642
12. Cotter MA, Florell SR, Leachman SA, Grossman D (2007) Absence of senescence-associated beta-galactosidase activity in human melanocytic nevi in vivo. J Invest Dermatol 127:2469-71
13. Cotter MA, Florell SR, Leachman SA, Grossman D (2008) Response to Gray- Schopfer et al. and Michaloglou et al.. J Invest Dermatol 128:1583-4
14. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H et al. (2005) Distinct sets of genetic alterations in melanoma. N Engl J Med 353:2135-47
15. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417:949-54
16. Denoyelle C, Abou-Rjaily G, Bezrookove V, Verhaegen M, Johnson TM, Fullen DR et al. (2006) Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway. Nat Cell Biol 8:1053-63
17. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C et al. (1995) A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA 92:9363-7
18. Dong J, Phelps RG, Qiao R, Yao S, Benard O, Ronai Z et al. (2003) BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res 63:3883-5
19. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D et al. (1998) A third generation lentivirus vector with a conditional packaging system. J Virol 72:8463-71
20. Goldstein AM, Chan M, Harland M, Gillanders EM, Hayward NK, Avril MF et al. (2006a) High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and Uveal melanoma across GenoMEL. Cancer Res 66:9818-28
21. Goldstein AM, Chan M, Harland M, Hayward NK, Demenais F, Bishop DT et al. (2006b) Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J Med Genet 44:99-106
22. Goydos JS, Mann B, Kim HJ, Gabriel EM, Alsina J, Germino FJ et al. (2005) Detection of B-RAF and N-RAS mutations in human melanoma. J Am Coll Surg 200:362-70
23. Gray-Schopfer VC, Cheong SC, Chong H, Chow J, Moss T, Abdel-Malek ZA et al. (2006) Cellular senescence in naevi and immortalisation in melanoma: a role for p16? Br J Cancer 95:496-505
24. Gruis NA, van der Velden PA, Sandkuijl LA, Prins DE, Weaver-Feldhaus J, Kamb A et al. (1995) Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds. Nat Genet 10:351-3
25. Ha L, Ichikawa T, Anver M, Dickins R, Lowe S, Sharpless NE et al. (2007) ARF functions as a melanoma tumor suppressor by inducing p53-independent senescence. Proc Natl Acad Sci USA 104:10968-73
26. Halaban R, Ghosh S, Duray P, Kirkwood JM, Lerner AB (1986) Human melanocytes cultured from nevi and melanomas. J Invest Dermatol 87:95-101
27. Huot TJ, Rowe J, Harland M, Drayton S, Brookes S, Gooptu C et al. (2002) Biallelic mutations in p16(INK4a) confer resistance to Ras- and Etsinduced senescence in human diploid fibroblasts. Mol Cell Biol 22:8135-43
28. Jiang CC, Chen LH, Gillespie S, Kiejda KA, Mhaidat N, Wang YF et al. (2007) Tunicamycin sensitizes human melanoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by upregulation of TRAIL-R2 via the unfolded protein response. Cancer Res 67:5880-8
29. Jones R, Ruas M, Gregory F, Moulin S, Delia D, Manoukian S et al. (2007) A CDKN2A mutation in familial melanoma that abrogates binding of p16INK4a to CDK4 but not CDK6. Cancer Res 67:9134-41
30. Korgaonkar C, Hagen J, Tompkins V, Frazier AA, Allamargot C, Quelle FW et al. (2005) Nucleophosmin (B23) targets ARF to nucleoli and inhibits its function. Mol Cell Biol 25:1258-71
31. Kumar R, Angelini S, Snellman E, Hemminki K (2004) BRAF mutations are common somatic events in melanocytic nevi. J Invest Dermatol 122:342-8
32. Leikam C, Hufnagel A, Schartl M, Meierjohann S (2008) Oncogene activation in melanocytes links reactive oxygen to multinucleated phenotype and senescence. Oncogene 22:22
33. McKeller RN, Fowler JL, Cunningham JJ, Warner N, Smeyne RJ, Zindy F et al. (2002) The Arf tumor suppressor gene promotes hyaloid vascular regression during mouse eye development. Proc Natl Acad Sci USA 99:3848-53
34. Michaloglou C, Soengas MS, Mooi WJ, Peeper DS (2008) Comment on "Absence of senescence-associated beta-galactosidase activity in human melanocytic nevi in vivo". J Invest Dermatol 128:1582-3; author reply 1583-4
35. Michaloglou C, Vredeveld LC, Soengas MS, Denoyelle C, Kuilman T, van der Horst CM et al. (2005) BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436:720-4
36. Narita M, Nunez S, Heard E, Lin AW, Hearn SA, Spector DL et al. (2003) Rbmediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 113:703-16
37. Palmero I, Pantoja C, Serrano M (1998) p19ARF links the tumour suppressor p53 to Ras. Nature 395:125-6
38. Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM et al. (2003) High frequency of BRAF mutations in nevi. Nat Genet 33:19-20
39. Pomerantz J, Schreiber-Agus N, Lie'geois NJ, Silverman A, Alland L, Chin L et al. (1998) The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92:713-23
40. Poynter JN, Elder JT, Fullen DR, Nair RP, Soengas MS, Johnson TM et al. (2006) BRAF and NRAS mutations in melanoma and melanocytic nevi. Melanoma Res 16:267-73
41. Reiser J (2000) Production and concentration of pseudotyped HIV-1-based gene transfer vectors. Gene Therapy 7:910-3
42. Rizos H, Darmanian AP, Indsto JO, Shannon JA, Kefford RF, Mann GJ (1999) Multiple abnormalities of the p16INK4a-pRb regulatory pathway in cultured melanoma cells. Melanoma Res 9:10-9
43. Schroder M, Kaufman RJ (2005) The mammalian unfolded protein response. Annu Rev Biochem 74:739-89
44. Serrano M, Hannon GJ, Beach D (1993) A new regulatory motif in cellcycle control causing specific inhibition of cyclin D/CDK4. Nature 366:704-7
45. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW (1997) Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 85:593-602
46. Sharpless E, Chin L (2003) The INK4a/ARF locus and melanoma. Oncogene 22:3092-8
47. Shaw RJ, Cantley LC (2006) Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441:424-30
48. Stahl JM, Sharma A, Cheung M, Zimmerman M, Cheng JQ, Bosenberg MW et al. (2004) Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res 64:7002-10
49. Stott FJ, Bates S, James MC, McConnell BB, Starborg M, Brookes S et al. (1998) The alternative product from the human CDKN2A locus, p14ARF, participates in a regulatory feedback loop with p53 and MDM2. EMBO J 17:5001-14
50. Sviderskaya EV, Gray-Schopfer VC, Hill SP, Smit NP, Evans-Whipp TJ, Bond J et al. (2003) p16/cyclin-dependent kinase inhibitor 2A deficiency in human melanocyte senescence, apoptosis, and immortalization: possible implications for melanoma progression. J Natl Cancer Inst 95:723-32
51. Uribe P, Wistuba II, Gonzalez S (2003) BRAF mutation: a frequent event in benign, atypical, and malignant melanocytic lesions of the skin. Am J Dermatopathol 25:365-70
52. Voorhoeve PM, Agami R (2003) The tumor-suppressive functions of the human INK4A locus. Cancer Cell 4:311-9
53. Wajapeyee N, Serra RW, Zhu X, Mahalingam M, Green MR (2008) Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell 132:363-74
54. Zhang Y, Xiong Y, Yarbrough WG (1998) ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92:725-34
55. Zindy F, Quelle DE, Roussel MF, Sherr CJ (1997) Expression of the p16INK4a tumor suppressor versus other INK4 family members during mouse development and aging. Oncogene 15:203-11
56. Zindy F, Williams RT, Baudino TA, Rehg JE, Skapek SX, Cleveland JL et al. (2003) Arf tumor suppressor promoter monitors latent oncogenic signals in vivo. Proc Natl Acad Sci USA 100:15930-5